Notably, the small molecule inhibitor NP-G2-044 targeting FSCN1 has shown efficacy in ocular neovascularization (Bai et al., 2023), hinting at its potential in PCa as it inhibits cell migration and filopodia formation. This evidence concerns the gene FSCN1 and posterior cortical atrophy.